Renata begins exporting medicines to Portugal for the first time
Graphics: Agamir Somoy
Renata PLC, a listed pharmaceutical manufacturer on the stock exchange, has started exporting medicines to Portugal for the first time as part of its expansion into Europe. The company has already dispatched its first consignment to the country, according to information from the Dhaka Stock Exchange (DSE).
The company stated that the first shipment included Amantadine 100 mg capsules, manufactured at its EU-GMP-approved Rajendrapur general production facility, and Fludrocortisone 0.1 mg and Cabergoline 0.5 mg tablets, produced at its Mirpur potent production facility. Both manufacturing facilities are EU-GMP approved.
According to Renata, entering the Portuguese market is a significant milestone in the company's international expansion strategy across Europe. The company expects that this will further strengthen its presence in the European market.
Earlier, on July 3, Renata announced that it had received approval to export and market its Levothyroxine Sodium tablets in six European Union countries. Under the decentralized approval procedure, marketing authorization was granted for the drug in Ireland, Germany, Italy, Poland, Portugal, and Malta.
The company has taken the initiative to enter these new European markets to ensure a safe, high-quality, and reliable supply of this medication used for thyroid disorders. The approved Levothyroxine Sodium tablets will be manufactured at Renata's EU-GMP-approved high-potency production facility.
Listed on the stock exchange in 1979, Renata has a paid-up capital of Tk 114.69 crore. Of the company's total shares, 51.29% are held by entrepreneurs and directors, 21.97% by institutional investors, 18.85% by foreign investors, and the remaining 7.89% by general shareholders.
